Jason Gardner, D.Phil
Jason is CEO, President and Cofounder of Magenta Therapeutics, a biotechnology company created to transform stem cell transplantation. He joined Atlas Venture in November 2015 as an Entrepreneur-in-Residence to create Magenta with Third Rock Ventures. He has more than 20 years experience in stem cell science and industry leadership roles. He worked at GSK for 11 years, most recently as Vice President and Head of the R&D Satellite in Boston. He created and led the Regenerative Medicine Unit, established partnerships with The Harvard Stem Cell Institute, and The Telethon Institute for Gene Therapy, from which the first stem cell medicine (Strimvelis™) was approved. Prior to that, Jason was the Head of the Center of Excellence for External Drug Discovery (CEEDD) and was a member of the clinical project team that led the late stage development and NDA approval for Tykerb™ for breast cancer.
Jason completed a postdoctoral fellowship in hematopoietic stem cells with Professor David Scadden at Harvard Medical School. He was educated in the U.K. and holds a doctorate from Oxford University and graduate and undergraduate degrees from Cambridge University.